Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis
Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pensoft Publishers
2020-09-01
|
| Series: | Folia Medica |
| Subjects: | |
| Online Access: | https://foliamedica.bg/article/48742/download/pdf/ |
| _version_ | 1818642580746797056 |
|---|---|
| author | Dionysia D. Fermeli Theodoros D. Marantos Alexandros-Leonidas D. Liarakos George D. Panayiotakopoulos Vasileios K. Dedes Georgios I. Panoutsopoulos |
| author_facet | Dionysia D. Fermeli Theodoros D. Marantos Alexandros-Leonidas D. Liarakos George D. Panayiotakopoulos Vasileios K. Dedes Georgios I. Panoutsopoulos |
| author_sort | Dionysia D. Fermeli |
| collection | DOAJ |
| description | Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment.  |
| first_indexed | 2024-12-16T23:45:19Z |
| format | Article |
| id | doaj.art-cf98bdf3036b4d2e89409aa046497bfe |
| institution | Directory Open Access Journal |
| issn | 1314-2143 |
| language | English |
| last_indexed | 2024-12-16T23:45:19Z |
| publishDate | 2020-09-01 |
| publisher | Pensoft Publishers |
| record_format | Article |
| series | Folia Medica |
| spelling | doaj.art-cf98bdf3036b4d2e89409aa046497bfe2022-12-21T22:11:31ZengPensoft PublishersFolia Medica1314-21432020-09-0162344445210.3897/folmed.62.e4874248742Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant TuberculosisDionysia D. Fermeli0Theodoros D. Marantos1Alexandros-Leonidas D. Liarakos2George D. Panayiotakopoulos3Vasileios K. Dedes4Georgios I. Panoutsopoulos5 General Hospital of SpartaUniversity of Athens, Attikon General HospitalGeorge Eliot HospitalUniversity of PatrasUniversity of PeloponneseUniversity of PeloponneseTuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment. https://foliamedica.bg/article/48742/download/pdf/adverse effectsefficacyextensively drug-resist |
| spellingShingle | Dionysia D. Fermeli Theodoros D. Marantos Alexandros-Leonidas D. Liarakos George D. Panayiotakopoulos Vasileios K. Dedes Georgios I. Panoutsopoulos Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis Folia Medica adverse effects efficacy extensively drug-resist |
| title | Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis |
| title_full | Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis |
| title_fullStr | Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis |
| title_full_unstemmed | Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis |
| title_short | Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis |
| title_sort | linezolid a promising agent for the treatment amp nbsp of multiple and extensively drug resistant amp nbsp tuberculosis |
| topic | adverse effects efficacy extensively drug-resist |
| url | https://foliamedica.bg/article/48742/download/pdf/ |
| work_keys_str_mv | AT dionysiadfermeli linezolidapromisingagentforthetreatmentampnbspofmultipleandextensivelydrugresistantampnbsptuberculosis AT theodorosdmarantos linezolidapromisingagentforthetreatmentampnbspofmultipleandextensivelydrugresistantampnbsptuberculosis AT alexandrosleonidasdliarakos linezolidapromisingagentforthetreatmentampnbspofmultipleandextensivelydrugresistantampnbsptuberculosis AT georgedpanayiotakopoulos linezolidapromisingagentforthetreatmentampnbspofmultipleandextensivelydrugresistantampnbsptuberculosis AT vasileioskdedes linezolidapromisingagentforthetreatmentampnbspofmultipleandextensivelydrugresistantampnbsptuberculosis AT georgiosipanoutsopoulos linezolidapromisingagentforthetreatmentampnbspofmultipleandextensivelydrugresistantampnbsptuberculosis |